# AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

> **NCT04885998** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 23 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Tarlatamab
- **DRUG:** AMG 404

## Key facts

- **NCT ID:** NCT04885998
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-27
- **Primary completion:** 2023-07-12
- **Final completion:** 2024-09-11
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04885998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04885998, "AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04885998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*